Współczesna Onkologia

Radiotherapy and immunotherapy in oligometastatic lung cancer: toward an optimal therapeutic balance – a narrative review

Artur Bandura 1
,
Michał Dąbrowski 2
,
Adrianna Kucharska 2
,
Julia Brymora 2
,
Rafał Dziadziuszko 1

  1. Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland

  2. Student Scientific Circle of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland

Contemp Oncol (Pozn) 2026; 30 (3)

DOI: https://doi.org/10.5114/wo.2026.164740
Data publikacji online: 2026/09/11
Article file
Radiotherapy and immunotherapy.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Torresan S, Costa J, Zanchetta C, de Marchi L, Rizzato S, Cortiula F. Oligometastatic NSCLC: current perspectives and future challenges. Curr Onco 2025; 32: 75.
  2. Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 358-376.
  3. Lung cancer survival rates. Available from: https://www.cancer.org/cancer/types/lung-cancer/detection-diagnosis-staging/survival-rates.html.
  4. Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, KindtsI, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol 2020; 148: 157-166.
  5. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13: 8-10..
  6. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011; 8: 378-382
  7. Mentink JF, Paats MS, Dumoulin DW, Cornelissen R, Elbers JBW, Maat APWM, et al. Defining oligometastatic non-small cell lung cancer: concept versus biology, a literature review. Transl Lung Cancer Res 2021; 10: 3329-3338.
  8. Hendriks LEL, Dooms C, Berghmans T, Novello S, Levy A, de Ruysscher D, et al. Defining oligometastatic non-small cell lung cancer: a simulated multidisciplinary expert opinion. Eur J Cancer 2019; 123: 28-35.
  9. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, de Souza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 2020; 21: e18-28.
  10. Dingemans AMC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, et al. Definition of synchronous oligometastatic non-small cell lung cancer-a consensus report. J Thorac Oncol 2019; 14: 2109-2119.
  11. Bandura A, Dinh PT, Wrona A, Konopa K, Dziadziuszko R. Treatment of oligometastatic non-small cell lung cancer with radio- therapy – single-centre experience. Contemp Oncol (Pozn) 2025; 29: 179-187.
  12. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 2019; 37: 537-546.
  13. Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 2021; 398: 1344-1357.
  14. Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019; 393: 1819-1830.
  15. Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Mene­zes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open- label, phase 3 trial. Lancet Oncol 2021; 22: 198-211.
  16. Lee P, Loo BW, Biswas T, Ding GX, El Naqa IM, Jackson A, et al. Local control following stereotactic body radiation therapy for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2019; 110: 160.
  17. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 2020; 38: 2830-2838.
  18. Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 2018; 4: e173501.
  19. Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol 2019; 37: 1558-1565.
  20. Belaroussi Y, Bouteiller F, Bellera C, Pasquier D, Perol M, Debieu- vre D, et al. Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting. Sci Rep 2023; 13: 9584.
  21. Wang M, Li S, Li R, Ning F, Tian L. Efficacy and mechanism of combining radiotherapy and immunotherapy in stage IV non-small cell lung cancer. Curr Treat Options Oncol 2024; 25: 1605-1614.
  22. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013; 105: 256-265.
  23. Yang S, Liu X, Yu J, Chen X, Liu X, Zhao S, et al. Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER): a randomized phase 2 trial. Signal Transduct Target Ther 2025; 10: 365.
  24. Samuel E, Lie G, Balasubramanian A, Hiong A, So Y, Voskoboy- nik M, et al. Impact of radiotherapy on the efficacy and toxicity of anti-PD-1 inhibitors in metastatic NSCLC. Clin Lung Cancer 2021; 22: e425-430.
  25. Bozorgmehr F, Chung I, Fischer JR, Bischof M, Atmaca A, Wetzel S, et al. Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415). Clin Exp Metastasis 2025; 42: 42.
  26. Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Gold- man JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 2017; 18: 895-903.
  27. Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med 2021; 9: 467-475.
  28. Huang J, Theelen WSME, Belcaid Z, Najjar M, van der Geest D, Singh D, et al. Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer. Nature Cancer 2025; 6: 1676-1692.
  29. Gao J, Lan A, Yang X, Chu L, Chu X, Zhou Y, et al. Early local therapy in combination with PD-1/PD-L1 inhibitors in oligometastatic non-small cell lung cancer: results from a prospective multicenter observational study. Cancer Immunol Immunother 2025; 74: 152.
  30. Lee HI, Choi EK, Kim SS, Shin YS, Park J, Choi CM, et al. Local ablative therapy combined with pembrolizumab in patients with synchronous oligometastatic non-small cell lung cancer: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys 2024; 120: 698-707.
  31. Standard maintenance therapy (SMT) vs local consolidative radiation therapy and SMT in OM-NSCLC. Available from: https://clinicaltrials.gov/study/NCT05278052.
  32. PD-1 inhibitor and chemotherapy with concurrent irradiation at varied tumour sites in advanced non-small cell lung cancer. Available from: https://clinicaltrials.gov/study/NCT03774732?cond=NCT03774732&rank=1.
  33. Doyen J, Besse B, Texier M, Bonnet N, Levy A. PD-1 inhibitor and chemotherapy with concurrent irradiation at varied tumor sites in advanced non-small cell lung cancer: the prospective randomized phase 3 NIRVANA-lung trial. Clin Lung Cancer 2022 M; 23: e252-256.
  34. Nivolumab and ipilimumab with or without local consolidation therapy in treating patients with stage IV non-small cell lung cancer. Available from: https://clinicaltrials.gov/study/NCT03391869?term=NCT03391869&viewType=Table&rank=1.
  35. Addition of hypofractionated high dose radiation in oligometastatic disease. Available from: https://clinicaltrials.gov/study/NCT06141070?term=NCT06141070&viewType=Table&rank=1.
  36. First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients. Available from: https://clinicaltrials.gov/study/NCT06840782.
  37. NCCN Clinical Practice Guidelines on Non-Small Cell Lung Cancer v. 5.2026. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
  38. Iyengar P, Hu C, Gomez DR, Timmerman RD, Simone CB, Robinson CG, et al. NRG-LU002: randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2024; 42: 8506-8506.
  39. Han H, Li L, Park T, Yang Y, Alai G, Zhong C, et al. Efficacy and safety of local consolidative therapy combined with systemic therapy in driver-negative oligometastatic non-small cell lung cancer: a systematic review and meta-analysis. Front Oncol 2026; 16: 1820515.
  40. Herbst RS, Garon EB, Dong-Wan K, Cho BC, Perez-Gracia JL, Han JY, et al. Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 Study. J Clin Oncol 2020; 38: 1580-1591.
  41. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540-1550.
  42. Peters S, Cho BC, Luft AV, Alatorre-Alexander J, Geater SL, Laktionov K, et al. Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic NSCLC: five-year overall survival outcomes from the phase 3 POSEIDON trial. J Thor Oncol 2025; 20: 76-93.
  43. Pandey T, Bhatti SA. Efficacy and safety of two-year fixed versus continuous immune checkpoint inhibitor therapy in advanced or metastatic non-small cell lung cancer: a systematic review. Cancer Immun Immunother 2025; 74: 317.
  44. Rousseau A, Michiels S, Simon-Tillaux N, Lolivier A, Bonastre J, Planchard D, et al. Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study. Lancet Reg Health Eur 2024; 43: 100970.
  45. Sun L, Bleiberg B, Hwang WT, Marmarelis ME, Langer CJ, Singh A, et al. Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer. JAMA Oncol 2023; 9: 1075-1082.
  46. Bandura A, Kurlapski M, Kamińska M, Dziadziuszko R, Jassem J. Profound neutropenia related to consolidation durvalumab treatment following concurrent radiochemotherapy in a patient with stage III non-small cell lung cancer. Pol Arch Intern Med 2022; 132: 16161.
  47. Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 1217-1238.
  48. Geier M, Descourt R, Corre R, Léveiller G, Lamy R, Goarant É, et al. Duration of nivolumab for pretreated, advanced non-small-cell lung cancer. Cancer Med 2020; 9: 6923-6932.
  49. Elghawy O, Barsouk A, Sussman JH, Bleiberg BA, Reed-Guy L, D’Avella C, et al. Late immune-related adverse events after at least two years of immune checkpoint inhibitor therapy: incidence and association with survival in patients with advanced NSCLC. JTO Clin Res Rep 2025; 6: 100851.
  50. Immunotherapy consolidation after radical treatment of synchronous oligo-metastatic NSCLC. Available from: https://clinicaltrials.gov/study/NCT06219317.
  51. Jasper K, Stiles B, McDonald F, Palma DA. Practical management of oligometastatic non-small-cell lung cancer. J Clin Oncol 2022; 40: 635-641.
  52. Iyengar P, All S, Berry MF, Boike TP, Bradfield L, Dingemans AMC, et al. Treatment of oligometastatic non-small cell lung cancer: an ASTRO/ESTRO clinical practice guideline. Pract Radiat Oncol 2023; 13: 393-412.
  53. Li Q, Ma H, Zheng R, Cai L, Zhang Y, Ling Y, et al. Durvalumab combined with chemotherapy and SABR therapy in patients with oligometastatic non-small cell lung cancer: a multicenter phase 2 study. Int J Radiat Oncol Biol Phys 2026; 124: 1371-1381.
  54. Remon J, Levy A, Gille R, Martel-Lafay I, Bortolot M, Hendriks LEL, et al. Unresectable stage III non-small-cell lung cancer: state of the art and challenges. Nat Rev Clin Oncol 2026; 23: 22-39.
  55. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377: 1919-1929.
  56. Jongbloed M, Damhuis RAM, van Geffen WH, de Boer P, Huijs JWJ, Dursun S, et al. Effect of treatment sequencing on outcome of patients with non-small cell lung cancer with a synchronous solitary extrathoracic metastasis. Lung Cancer 2026; 212: 108889.
  57. Mahmood U, Josephides E, Coupe N, Smith D, Ahmad S, Al-Salihi O, et al. Outcomes following radiotherapy for oligoprogressive NSCLC on immune checkpoint inhibitors: a real-world, multinational experience. Cancers (Basel) 2025; 18: 71.
  58. Santonja C, Gougis P, Dumas E, Debord CR, Merle P, Belliere A, et al. Radiotherapy for oligoprogressive disease in non-small cell lung cancer treated with pembrolizumab in first-line setting: a retrospective study. Transl Lung Cancer Res 2024; 13: 3603-3615.
  59. Kang H, Do W, Ahn YC, Chie EK, Rim CH. A new proposal of simplified classification of non-small cell lung cancer oligometastases for easy applicability through systematic literature analysis and meta-analysis validation. Eur J Cancer 2024; 212: 115043.
  60. Friedes C, Yegya-Raman N, Zhang S, Iocolano M, Cohen RB, Aggarwal C, et al. Patterns of failure in metastatic non-small cell lung cancer (mNSCLC) treated with first line pembrolizumab and use of local therapy in patients with oligoprogression. J Clin Oncol 2023; 41: e21054-e21054.
  61. Xu Y, Li H, Fan Y. Progression patterns, treatment, and prognosis beyond resistance of responders to immunotherapy in advanced non-small cell lung cancer. Front Oncol 2021; 11: 642883.
  62. Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (consolidative use of radiotherapy to block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet 2024; 403: 171-182.
  63. Schaft N, Dörrie J, Schuler G, Schuler-Thurner B, Sallam H, Klein S, et al. The future of affordable cancer immunotherapy. Front Immunol 2023; 14: 1248867.
  64. Slotman BJ, Van Tinteren H, Praag JO, Knegjens JL, El Sharo- uni SY, Hatton M, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 2015; 385: 36-42.
  65. Wróbel D, Wojewoda B, Ziółek W, Potocki PM, Borowczak J. Consolidative thoracic radiotherapy in the immunotherapy era for extensive-stage small cell lung cancer: a systematic review and meta-analysis with emphasis on brain and liver metastases. Radiother Oncol 2026; 216: 111328.
  66. Concurrent thoracic radiotherapy (TRT), platinum/etoposide chemotherapy, and durvalumab immunotherapy in extensive-stage (ES) small cell lung cancer (SCLC): A phase III trial – ASCO. Available from: https://www.asco.org/abstracts-presentations/259316.
  67. Li W, Wu P, Liang Z, Li L, Chen Y, Zhang W, et al. Efficacy and safety of tyrosine kinase inhibitors with thoracic radiotherapy for patients with oncogene-mutated non-small cell lung cancer: a meta- analysis. Radiat Oncol 2024; 19: 154.
  68. Sampath S, Rashdan S, Iyengar P, Mickel TA, Zhang S, Ahn C, et al. Osimertinib plus consolidative radiotherapy for advanced EGFR mutant non-small cell lung cancer: a multicentre, single-arm, phase 2 trial. EClinicalMedicine 2025; 87: 103435.
  69. Elamin YY, Gandhi S, Antonoff M, Gibbons D, Negrao MV, Casco- ne T, et al. LBA72 NorthStar: a phase II randomized study of osimertinib (OSI) with or without local consolidative therapy (LCT) for metastatic EGFR-mutant non-small cell lung cancer (NSCLC). Ann Oncol 2025; 36: S1614.
  70. Chen H, Yu L, Liang F, Zhou Y, Chu L, Chu X, et al. Consolidative stereotactic radiotherapy for oligo-residual non-small cell lung cancer after first-line chemoimmunotherapy: a single-arm, phase 2 trial from China. PLoS Med 2025; 22: e1004680.
  71. Xie W, Yan M, Wen F, Wu Y, Cheng X, Hu J, et al. Local consolidative therapy extends survival in metastatic NSCLC with oligoresidual disease following first-line immunotherapy, irrespective of PD-L1 expression. Sci Rep 2025; 15: 36765.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Coverage in
Indexed in
pubmed
Integrated with
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications